These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20438440)

  • 1. Recent therapeutic advances for treating medulloblastoma: focus on new molecular targets.
    Schmidt AL; Brunetto AL; Schwartsmann G; Roesler R; Abujamra AL
    CNS Neurol Disord Drug Targets; 2010 Jul; 9(3):335-48. PubMed ID: 20438440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapy.
    Prados MD; Wara W; Edwards MS; Ater J; Rabbit J; Lamborn K; Davis R; Levin VA
    Pediatr Neurosurg; 1996 Oct; 25(4):174-81. PubMed ID: 9293544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of the molecular genetics and chemotherapeutic treatment of adult and paediatric medulloblastoma.
    Newton HB
    Expert Opin Investig Drugs; 2001 Dec; 10(12):2089-104. PubMed ID: 11772307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Novel Medulloblastoma Cell-Targeting Peptides for Use in Selective Chemotherapy Drug Delivery.
    Tjandra KC; McCarthy N; Yang L; Laos AJ; Sharbeen G; Phillips PA; Forgham H; Sagnella SM; Whan RM; Kavallaris M; Thordarson P; McCarroll JA
    J Med Chem; 2020 Mar; 63(5):2181-2193. PubMed ID: 31347843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targets for medulloblastoma.
    Wlodarski PK; Jozwiak J
    Expert Opin Ther Targets; 2008 Apr; 12(4):449-61. PubMed ID: 18348681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Childhood medulloblastoma: current status of biology and treatment.
    Klesse LJ; Bowers DC
    CNS Drugs; 2010 Apr; 24(4):285-301. PubMed ID: 20297854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and molecular alterations across medulloblastoma subgroups.
    Skowron P; Ramaswamy V; Taylor MD
    J Mol Med (Berl); 2015 Oct; 93(10):1075-84. PubMed ID: 26350064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting metabotropic glutamate receptors in the treatment of primary brain tumors.
    Iacovelli L; Orlando R; Rossi A; Spinsanti P; Melchiorri D; Nicoletti F
    Curr Opin Pharmacol; 2018 Feb; 38():59-64. PubMed ID: 29525720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medulloblastoma development: tumor biology informs treatment decisions.
    Gopalakrishnan V; Tao RH; Dobson T; Brugmann W; Khatua S
    CNS Oncol; 2015; 4(2):79-89. PubMed ID: 25768332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of medulloblastoma and current treatment outlook.
    Jozwiak J; Grajkowska W; Wlodarski P
    Med Res Rev; 2007 Nov; 27(6):869-90. PubMed ID: 17089411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study.
    Packer RJ; Goldwein J; Nicholson HS; Vezina LG; Allen JC; Ris MD; Muraszko K; Rorke LB; Wara WM; Cohen BH; Boyett JM
    J Clin Oncol; 1999 Jul; 17(7):2127-36. PubMed ID: 10561268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of patients of high-risk group of medulloblastoma with the adjuvant lomustine, cisplatin, and vincristine chemotherapy.
    Rutkauskiene G; Labanauskas L
    Medicina (Kaunas); 2005; 41(12):1026-34. PubMed ID: 16401959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medulloblastoma: clinical and biologic aspects.
    Packer RJ; Cogen P; Vezina G; Rorke LB
    Neuro Oncol; 1999 Jul; 1(3):232-50. PubMed ID: 11550316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors.
    Höland K; Salm F; Arcaro A
    Curr Cancer Drug Targets; 2011 Oct; 11(8):894-918. PubMed ID: 21861842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABCB1 in children's brain tumours.
    Coyle B; Kessler M; Sabnis DH; Kerr ID
    Biochem Soc Trans; 2015 Oct; 43(5):1018-22. PubMed ID: 26517917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.
    Triscott J; Lee C; Foster C; Manoranjan B; Pambid MR; Berns R; Fotovati A; Venugopal C; O'Halloran K; Narendran A; Hawkins C; Ramaswamy V; Bouffet E; Taylor MD; Singhal A; Hukin J; Rassekh R; Yip S; Northcott P; Singh SK; Dunham C; Dunn SE
    Cancer Res; 2013 Nov; 73(22):6734-44. PubMed ID: 24019381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of FOXM1 by thiostrepton sensitizes medulloblastoma to the effects of chemotherapy.
    Lin J; Zheng Y; Chen K; Huang Z; Wu X; Zhang N
    Oncol Rep; 2013 Oct; 30(4):1739-44. PubMed ID: 23912794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapy of infantile malignant brain tumors: current status?
    Kalifa C; Grill J
    J Neurooncol; 2005 Dec; 75(3):279-85. PubMed ID: 16195802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of fibroblast growth factors (FGFs) for medulloblastoma may correlate with FGF receptor expression and tumor variant.
    Duplan SM; Théorêt Y; Kenigsberg RL
    Clin Cancer Res; 2002 Jan; 8(1):246-57. PubMed ID: 11801566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RalA is overactivated in medulloblastoma.
    Ginn KF; Fangman B; Terai K; Wise A; Ziazadeh D; Shah K; Gartrell R; Ricke B; Kimura K; Mathur S; Borrego-Diaz E; Farassati F
    J Neurooncol; 2016 Oct; 130(1):99-110. PubMed ID: 27566179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.